Psychopharmacology of schizophrenia: a European view.
This article describes how psychopharmacological therapy is applied in Yugoslavia and other countries in Central Europe. The first part of the article summarizes experience and customary use of psychopharmacological substances in relation to clinical syndromes, course of disease, and dominant symptoms. In the second part of the article, the experience obtained in treatment with combinations of drugs and in prolonged pharmacotherapy of schizophrenia is described. Finally, the last section of the article addresses the social implications of psychopharmacological treatment and presents some of the problems and disadvantages that accompany this form of treatment.
Bohacek
N
N
D000208:Acute Disease; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D003692:Delayed-Action Preparations; D003866:Depressive Disorder / Q000139:chemically induced; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000517:prevention & control; D005060:Europe; D006801:Humans; D011619:Psychotropic Drugs / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D013997:Time Factors; D015022:Yugoslavia
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D011619:Psychotropic Drugs